SCHEDULE: FMR LLC Discloses 3.2% Stake in Bicara Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 3.2% of Bicara Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating beneficial ownership of 2,100,929 shares of Bicara Therapeutics Inc. common stock.
• This represents 3.2% of the total outstanding common stock as of March 31, 2026.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an investment company (IN).
• The filing confirms that no single other person's interest in Bicara Therapeutics' common stock exceeds five percent.
• Fidelity Management & Research Company LLC, IMPRESA MANAGEMENT LLC, and Strategic Advisers LLC are identified as entities with investment adviser (IA) classifications that are part of the reporting group.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports passive ownership without providing new strategic information or performance indicators.

Positives

• FMR LLC and Abigail P. Johnson have disclosed a significant, albeit passive, ownership stake in Bicara Therapeutics, which can be seen as a vote of confidence in the company's potential.
• The filing clarifies that no single entity holds more than 5% of the shares, suggesting a diversified institutional ownership base.

Negatives

• The filing is a Schedule 13G, which typically indicates passive investment and does not suggest any intention to influence or control the company's management or policies.

Risks

• As a passive investment, there is a risk that FMR LLC or Abigail P. Johnson could divest their shares, potentially impacting Bicara Therapeutics' stock price.
• The filing does not provide any strategic insights or forward-looking statements from FMR LLC regarding their investment thesis or future actions.

Future Outlook

The filing is a Schedule 13G, which reports passive beneficial ownership and does not contain forward-looking statements or guidance from the reporting persons regarding Bicara Therapeutics.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson indicates a significant institutional investor's passive stake in Bicara Therapeutics. Such filings are common for large asset managers and signal a level of interest, though not necessarily an active engagement in the company's strategic direction.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by FMR LLC may be viewed positively by some shareholders, indicating institutional interest. However, it does not imply active support or strategic involvement.
• Management: The filing does not suggest any immediate pressure or influence from FMR LLC on Bicara Therapeutics' management.
• Creditors: No direct impact on creditors is indicated by this passive ownership filing.

Next Steps

• Monitor future filings from FMR LLC and Abigail P. Johnson for any changes in beneficial ownership.
• Observe Bicara Therapeutics' operational and financial performance to assess the underlying value of the company.

Key Dates

Keywords

Bicara Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, SEC Filing, Common Stock, Beneficial Ownership, Investment Company, Holding Company, Institutional Investor